Back to News

Idorsia joins IQ Consortium

Idorsia joins IQ Consortium

August 8, 2022


The IQ Consortium is very pleased to announce its newest member, Idorsia

Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is a high-potential biopharmaceutical company, specialized in the discovery, development, and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options.

Idorsia will be represented on the IQ Board of Directors by Olivier Lambert and Markus von Raumer.